BioSpecifics Technologies Corp (BSTC) financial statements (2021 and earlier)

Company profile

Business Address 35 WILBUR ST
LYNBROOK, NY 11563
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments879910489828584
Cash and cash equivalents317195131418
Short-term investments84828584697167
Receivables14121819181716
Prepaid expense    1  
Other undisclosed current assets2111111
Total current assets:102112123109101103102
Noncurrent Assets
Operating lease, right-of-use asset0000   
Property, plant and equipment000    
Long-term investments and receivables34219171684
Long-term investments34219171684
Intangible assets, net (including goodwill)1111100
Intangible assets, net (excluding goodwill)1111100
Other noncurrent assets000    
Other undisclosed noncurrent assets     00
Total noncurrent assets:352210171794
TOTAL ASSETS:137134133127118112106
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1221112
Accounts payable000 000
Accrued liabilities1100101
Employee-related liabilities1100000
Taxes payable   0   
Other undisclosed accounts payable and accrued liabilities0010000
Debt 000   
Other undisclosed current liabilities0220 12
Total current liabilities:2431124
Noncurrent Liabilities
Long-term debt and lease obligation0000   
Operating lease, liability0000   
Liabilities, other than long-term debt00011  
Deferred income tax liabilities00011  
Total noncurrent liabilities:01111  
Total liabilities:2442124
Stockholders' equity
Stockholders' equity attributable to parent135129129124117110102
Common stock0000000
Treasury stock, value(12)(12)(12)(12)(11)(11)(11)
Additional paid in capital41404039393837
Retained earnings10710110197898377
Total stockholders' equity:135129129124117110102
TOTAL LIABILITIES AND EQUITY:137134133127118112106

Income statement (P&L) ($ in millions)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Revenues1141012998
Cost of revenue(1)      
Gross profit:1041012998
Operating expenses(3)(4)(4)(3)(2)(2)(3)
Operating income (loss):7(0)59775
Nonoperating income0001110
Investment income, nonoperating000 110
Income from continuing operations before income taxes:7069876
Income tax expense(1)(0)(1)(2)(2)(1)(1)
Net income available to common stockholders, diluted:5047664

Comprehensive Income ($ in millions)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Net income:5047664
Comprehensive income, net of tax, attributable to parent:5047664

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: